Company intelligence / Profile preview

Chia Tai

Lianyungang, Jiangsu, China

Ownership: Private
Employees: ~14000
Development stage: Other

Overview

CTTQ is a top-15 Chinese pharma with commercial presence in liver health, oncology, and other areas. It has been developing innovative drugs (e.g., biparatopic HER2 x HER2 antibody-drug conjugate TQB2102 now in multiple phase 3 breast cancer trials), established generics and biopharma lines, and maintains significant manufacturing and R&D capacity[1][3][5][8].

Therapeutic areas: EndocrinologyMen's HealthGastroenterologyPulmonologyOncologyWomen's Health
Modalities: Small moleculeAntibody-based immunotherapyProtein therapeuticsAptamerBiologic
Industry: Pharma

Partnerships

Harbour BioMed

Beyond the preview

Go deeper on Chia Tai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chia Tai.

Explore the full profile